Ryan PB, et al. - Data from four large US administrative claims databases were utilized to study the real-world comparative efficacy within the sodium glucose co-transporter 2 inhibitors (SGLT2i) class and compared with non-SGLT2i antihyperglycaemic agents. Researchers reported that canagliflozin and other SGLT2i agents exhibited hospitalization for heart failure (HHF) benefits consistent with clinical trial data. However, no increased risk of below-knee lower extremity (BKLE) amputation vs non-SGLT2i was found. It was noted that HHF and BKLE amputation results were similar in the subpopulation with established cardiovascular disease. Between canagliflozin and other SGLT2i, no consistent differences were noted.